Kawasaki Disease
Also known as: Mucocutaneous lymph node syndrome
Methodology & AI Transparency ⓘ
Kawasaki Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Kawasaki disease? Kawasaki disease is a rare illness that usually affects small children.
- 2 Real-world patient consensus: Diagnostic registry M30.3: Kawasaki Disease is managed within Heart & Vascular (aka Mucocutaneous lymph node syndrome).
- 3 Typical cash cost range: Clinicians assessing Kawasaki Disease focus on fibrotic extracellular matrix in Kawasaki Disease (M30.3: deposition) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Kawasaki Disease: maintaining High-Sensitivity Troponin I [Kawasaki Disease M30.3] within < 14 ng/L (M30.3).
Ask our AI Specialists anything about Kawasaki Disease
What Is Kawasaki Disease?
What is Kawasaki disease? Kawasaki disease is a rare illness that usually affects small children. Other names for the disease are Kawasaki syndrome and mucocutaneous lymph node syndrome. It is a type of vasculitis , which is inflammation of the blood vessels. Kawasaki disease is serious, but most children can fully recover if they are treated right away. What causes Kawasaki disease? Kawasaki disease happens when the immune system injures the blood vessels by mistake. Researchers do not fully know why this happens. But when it does, the blood vessels become inflamed and can narrow or close off. Genetics may play a role in Kawasaki disease.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Kawasaki Disease (M30.3) features fibrotic extracellular matrix in Kawasaki Disease (M30.3: deposition). Cross-referenced with NIH MeSH (Mucocutaneous Lymph Node Syndrome), therapeutic stabilization in heart & vascular is verified against Apolipoprotein B (ApoB) [Kawasaki Disease M30.3].
Common Symptoms & Clinical Signs
- • High fever lasting at least five days
- • A rash , often on the back, chest, and groin
- • Presentation of Kawasaki Disease (M30.3): reduced exercise tolerance in Kawasaki Disease (M30.3: and premature cardiovascular)
- • Secondary Kawasaki Disease clinical sign: exertional chest pressure in Kawasaki Disease (M30.3: or retrosternal tightness)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Kawasaki Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M30.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Kawasaki Disease M30.3] | < 14 ng/L (M30.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Kawasaki Disease M30.3] | < 70 mg/dL (M30.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Kawasaki Disease (M30.3: Fraction (LVEF)) | 55% – 70% (M30.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Kawasaki Disease
Treatment selection for Kawasaki Disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Kawasaki Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute: What a 6,291-Participant Study Found A high-dose loading of statins before PCI in patients with ACS reduces MACCE and reduces the risk of MI with no impact on mortality at 30 days. European journal of clinical pharmacology • 2022-01-15 • Meta-Analysis | N = 6,291 | 94/100 | PMID 34423376 ↗ |
| Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine and how the medicine works in the body of Single dose AQST-109 demonstrated PK exposures consistently bracketed within established levels for approved intramuscular epinephrine and autoinjectors, with a more rapid time-to-maximum plasma concentration and comparable PD... Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2026-04-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 41297629 ↗ |
Kawasaki Disease Patient Community & “People Like Me” Threads
Filter Kawasaki Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.